CMVR-related complications and other adverse events
CMVR, CMV end-organ disease, CMVR lesions, IRU, vitreous haemorrhage, glaucoma, vision loss, Glaucoma
OPTIC ATROPHY SECONDARY, ADVERSE EVENTS, ENDOPHTHALMITIS, OTHER COMPLICATION, OPTIC NERVE, GLAUCOMA, VITREOUS HAEMORRHAGE, ANTERIOR SYNECHIAE, GLAUCOMA, RETINAL DETACHMENT, COMPLICATIONS, COMPLICATIONS
Complications occurred in 35 eyes (52.2%; Zone I in 26 eyes and Zone II in 8 eyes) during the follow-up period. Regarding these complications, no significant difference was found between the two groups (
A CMVR lesion in Zone I was treated with injections of 0.4 mg ganciclovir. IRU developed in 9 eyes (13.4%) of 9 patients after the resolution of CMVR. All of these patients had stable CD4Six eyes (8.9%) of 6 patients had optic atrophy secondary to glaucoma or CMVR lesions involving the optic nerve. Three eyes in the cohort had poorly controlled glaucoma because of anterior synechia. Glaucoma treatment was provided, but the vision loss was irreversible. Other complications included vitreous haemorrhage in 4 eyes (5.9%) and CMVR relapse in 2 eyes (3.0%). No evidence was found for CMVR relapse in fellow eyes or newly developed CMV end-organ disease during follow-up. A transient increase in IOP occurred universally after IVI. No serious adverse events, such as high IOP, retinal detachment, vitreous haemorrhage, or endophthalmitis, occurred in association with IVI.